2023-03-20 16:00Financial Performance - The company achieved a record revenue of RMB 39,354,777,805.53 in 2022, representing a growth of 71.84% compared to 2021[20]. - Net profit attributable to shareholders reached RMB 8,813,713,033.51, marking a 72.91% increase from the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 8,260,289,685.19, which is a 103.27% increase year-over-year[20]. - The net cash flow from operating activities was RMB 10,616,029,916.68, reflecting a significant increase of 131.32% compared to 2021[20]. - The company's total assets at the end of 2022 were RMB 64,690,326,746.96, up 17.35% from the previous year[20]. - Basic earnings per share for 2022 were RMB 3.01, an increase of 72.00% compared to 2021[21]. - The weighted average return on net assets was 20.62%, an increase of 6.57 percentage points from the previous year[21]. - The net profit attributable to shareholders increased by 72.91% year-on-year, while the net profit excluding non-recurring gains and losses grew by 103.27%[23]. - The net cash flow from operating activities reached RMB 1,061,602.99 million, a 131.32% increase compared to the same period in 2021[23]. - Basic earnings per share increased by 72.00%, diluted earnings per share rose by 63.01%, and basic earnings per share excluding non-recurring gains and losses grew by 102.88%[23]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 8.9266 per 10 shares, totaling RMB 2,644,137,750.80 for the year 2022[4]. - There are no significant changes in the total share capital prior to the dividend distribution date[4]. - The net profit attributable to ordinary shareholders of the listed company for the consolidated financial statements is RMB 8,813,713,033.51, with a dividend payout ratio of 30%[144]. - The profit distribution plan has been approved by all directors, including independent non-executive directors, and will be submitted for approval at the annual general meeting[142]. Operational Risks and Compliance - The company has confirmed that there are no significant risks that could materially affect its operations during the reporting period[6]. - The company has outlined potential risks in its operations, which are detailed in the report[6]. - The company has not faced any violations of decision-making procedures regarding external guarantees[5]. - The company has not disclosed any forward-looking commitments that could be construed as guarantees to investors[5]. - The company emphasizes compliance and has established a robust internal control system, but risks remain if oversight of subsidiaries is insufficient[94]. - The company faces risks from a potential decline in demand for pharmaceutical research services, which could negatively impact business if industry growth slows or outsourcing ratios decrease[91]. - Regulatory changes in the pharmaceutical research services industry could pose risks if the company fails to adapt its operational strategies to comply with new policies and regulations[92]. Business Growth and Customer Base - In 2022, the company added over 1,400 new customers, with active customers exceeding 5,950[31]. - Revenue from U.S. customers was RMB 25.884 billion, a 113% year-on-year increase; revenue from Chinese customers was RMB 7.526 billion, up 30%[31]. - Revenue from the top 20 global pharmaceutical companies reached RMB 18.421 billion, a 174% increase year-on-year[31]. - Revenue from existing customers amounted to RMB 37.781 billion, reflecting a 77% growth compared to the previous year[31]. - The company achieved a total revenue of RMB 36.736 billion from clients using multiple business units, marking an 87% increase[31]. Research and Development - R&D expenses increased by 71.29% to RMB 1,613,953,441.33, reflecting the company's commitment to innovation[48]. - The company is committed to advancing digital transformation and optimizing data utilization across various business departments[89]. - The company plans to strengthen its service capabilities in new molecular types such as PROTAC, oligonucleotide drugs, and gene therapy, leveraging cutting-edge technologies[88]. - The company is focused on expanding its market presence and enhancing its research and development capabilities[125]. Environmental Management - The company has established an environmental protection mechanism and is classified as a key pollutant discharge unit by environmental protection authorities[156]. - The total SO₂ emissions from the company were 0.162 tons, with a concentration of 1.0 mg/m³, well below the standard limit of 200 mg/m³[157]. - The total NOx emissions were 6.30 tons, with a concentration of 49.9 mg/m³, also below the standard limit of 200 mg/m³[157]. - The company has implemented a waste management program to supervise and manage the generation, collection, classification, labeling, recording, storage, transportation, and disposal of waste[169]. - The company has established partnerships with qualified waste disposal units for the safe handling of hazardous waste, including animal carcasses and contaminated materials[183]. Governance and Management - The board of directors and management have ensured the accuracy and completeness of the annual report[2]. - The company has a complete business system and operates independently from the actual controller, with no business dependencies or competition[102]. - The board of directors includes a diverse group of experienced professionals, ensuring robust governance and strategic oversight[107]. - The company has maintained a consistent governance structure with independent directors overseeing key decisions[119]. - The total pre-tax remuneration for the Chairman and CEO, Ge Li, was CNY 41.97 million in the reporting period[104]. Future Outlook - The company expects a revenue growth of 5-7% in 2023, with WuXi Chemistry projected to grow by 36-38% and other business segments expected to grow by 20-23%[45]. - The company provided guidance for the next fiscal year, projecting revenue growth of 25% and aiming to reach $1.875 billion[109]. - New product launches are expected to contribute an additional $300 million in revenue, with a focus on innovative solutions in the biotech sector[109]. - The company is exploring potential acquisitions to bolster its portfolio, with a budget of $500 million allocated for strategic investments[109].